METHODS:
Administrative claims data from a large employer (n > 100,000) were analyzed. ADHD patients were identified as beneficiaries with one or more claims for ADHD in the study period . The ADHD patient sample was compared to a matched control sample. In addition to descriptive analysis, multivariate analysis involving logistic regression was used to estimate a model of the probability of having an accident. RESULTS: ADHD patients have a greater incidence of accidents than their controls (32% v. 20%). However, given that a patient has an accident, the average number of accident claims is the same between both groups (3.6 v. 3.5). Accident specific costs are greater for ADHD patients than controls ($209 vs. $131) because patients with this condition are more likely to have accidents. Among patients with accident claims, ADHD patients and controls had statistically similar costs. The multivariate analysis confirms the utilization patterns found in the descriptive analysis. The odds of having an accident for ADHD patients are 1.7 times as great as that for controls after taking account of all the other variables. CONCLUSIONS: ADHD is a significant predictor of having an accident. However, given that a person has an accident, ADHD patients generally have a similar number of accident claims and costs as their controls. , 1997 and March 31, 1999 and tracked through June 2000. Matched patients were randomly selected to populate three comparator groups: haloperidol, risperidone, and olanzapine. Primary endpoint was the duration on monotherapy. Secondary endpoint was whether costs decreased with greater duration on monotherapy. Psychiatric related costs were also aggregated by type of service. Analyses consisted of Cox proportional hazard models for time on monotherapy and linear regressions for cost. Three subset analyses were performed: patients aged 45 to 64, psychotic patients 65 or older, and patients with bipolar disorder. RESULTS: For psychotic patients 45 to 64 years old, quetiapine-treated patients remained on treatment for 284 days vs. 261 days for risperidone (P = 0.71), 284 vs. 144 for haloperidol (P < 0.01), and 284 vs. 147 for olanzapine (P < 0.01). Corresponding cost savings for this age
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